SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech announced that its co-founders, Ugur Sahin and Özlem Türeci,…

BioNTech SE · PRESS-RELEASE filed Mar 10, 2026 at 06:33 ET

At the news

MIXEDIMPACT 7/10

PRESS-RELEASE filed Mar 10, 2026 at 06:33 ET

BioNTech announced that its co-founders, Ugur Sahin and Özlem Türeci, will establish an independent biotechnology company focused on next-generation mRNA innovations, transitioning from their leadership roles by end of 2026. BioNTech plans to contribute mRNA-related rights and technologies to the new venture in exchange for a minority stake, aiming to sharpen its own focus on late-stage immunomodulators, ADCs, and mRNA candidates in oncology.

  • Co-founders Ugur Sahin and Özlem Türeci will launch a new independent biotech company focused on next-generation mRNA technologies.
  • Leadership transition expected by end of 2026; BioNTech is conducting an executive search for successors.
  • BioNTech will contribute mRNA-related rights and technologies to the new company in exchange for a minority stake, milestones, and royalties.
  • Binding agreement expected by end of H1 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access